Cargando…

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing numbe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ro, Jungsil, Cheng, Fiona Tsui-Fen, Sriuranpong, Virote, Villalon, Antonio, Smruti, B. K, Tsang, Janice, Yap, Yoon Sim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822111/ https://www.ncbi.nlm.nih.gov/pubmed/27066091 http://dx.doi.org/10.4048/jbc.2016.19.1.8

Ejemplares similares

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
por: Rau, Kun-Ming, et al.
Publicado: (2018)

Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice
por: Tanaka, Toshihiro, et al.
Publicado: (2017)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2017)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2016)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer
por: Donovan, Diana, et al.
Publicado: (2014)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
Publicado: (2015)

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
por: Satomi-Tsushita, Natsuko, et al.
Publicado: (2019)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells
por: CHUNHACHA, PREEDAKORN, et al.
Publicado: (2013)

Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
por: Kaewbubpa, Walennee, et al.
Publicado: (2016)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
por: Tremblay, Gabriel, et al.
Publicado: (2016)

Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients
por: Ditsatham, Chagkrit, et al.
Publicado: (2018)

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
por: Pivot, X., et al.
Publicado: (2016)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Keenan, Tanya E., et al.
Publicado: (2021)

Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
por: Chen, Pei-Hsin, et al.
Publicado: (2021)

Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
por: Lin, Yu-Ju, et al.
Publicado: (2021)

Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer
por: Chalasani, Pavani, et al.
Publicado: (2021)

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience − A Multicenter Retrospective Study
por: Jafri, Mariam, et al.
Publicado: (2022)

Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
por: Bun, Ayako, et al.
Publicado: (2023)

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
por: Kim, Jung Sun, et al.
Publicado: (2014)

Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study
por: Palapinyo, Sirinoot, et al.
Publicado: (2022)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2014)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
por: Fumet, Jean-David, et al.
Publicado: (2018)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
por: Mougalian, Sarah S., et al.
Publicado: (2021)

Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report
por: Xie, Xiao-Feng, et al.
Publicado: (2022)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Eribulin for Advanced Breast Cancer: A Drug Evaluation
por: Shablak, Alaaeldin
Publicado: (2013)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qn8b01pgipafi8jcqnigvp9pps